Story thread · 8 reports / 7 sources
Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
bloomberg.com · 5h · first report
How the coverage leans
Across 7 sources · syndicated copies counted once
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, betting on a technology that could mean patients need only one obesity shot every few months.
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.